BioSpace News Archive

SciSparc Ltd. today announced it received Ethics Committee approvals from Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel, to conduct the Company’s Phase IIb clinical study for SCI-110 in patients suffering from Tourette Syndrome (“TS”).

Laekna Therapeutics, a clinical-stage biotechnology company developing innovative medicines to treat cancer and liver diseases, today announced that two first patients have been dosed in the U.S. and China, respectively, in a Phase Ib/III clinical trial that evaluates the efficacy and safety of afuresertib.

Neuvivo, a late-clinical stage biopharmaceutical company developing a new ALS treatment, today announced that it has closed on an additional round of financing led by an international investment group.

Moleculin Biotech, Inc. today announced the commencement of dosing in its first-in-human Phase 1a study to evaluate the safety and pharmacokinetics (PK) of WP1122 in healthy volunteers for the treatment of COVID-19 (MB-301).

Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion ® Cosmetic Technology in Dermal Resurfacing Procedures.

Rapid Dose Therapeutics Corp. (“ RDT” ), ( CSE: DOSE) , a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, today announced that it plans to complete a private placement financing (the “ Financing ”) for up to $5,000,000 of gross proceeds, consisting of up to 5,000 units (the “ Units ”) at a price of $1,000 per Unit.

NovoMedix, LLC (“NovoMedix”), today announced that the National Heart, Lung, and Blood Institute division of the NIH has awarded NovoMedix a $2M Phase II SBIR grant to further the development of Novel Small Molecules that protect Triple-Negative Breast Cancer (TNBC) patients from the devastating long-term cardiotoxic effects of doxorubicin chemotherapy.

BioSig Technologies, Inc. announced the rollout of the Company’s national commercial launch campaign.

CorePath is excited to announce a partnership with Cizzle Biotechnology, a UK based diagnostics developer, to develop and offer a proprietary early-stage lung cancer test throughout the United States.

According to Vision Research Reports, the Europe mobility aids market was valued at USD 2.9 billion in 2021 and it is predicted to surpass around USD 3.99 billion by 2030 with a CAGR of 3.61% from 2022 to 2030.